We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Early Sepsis Recognition Platform Could Identify Pre-Symptomatic Patients at POC Using Culture-Free Diagnostic Test

By HospiMedica International staff writers
Posted on 14 Nov 2022
Print article
Image: An early sepsis recognition platform could be more rapid, affordable and accessible (Photo courtesy of Pexels)
Image: An early sepsis recognition platform could be more rapid, affordable and accessible (Photo courtesy of Pexels)

Early sepsis recognition is vital in improving patient prognosis and reducing mortality. Now, a new diagnostic system for early-stage sepsis condition could allow doctors to predict the future appearance and evolution of sepsis within a short period of time and thus, provide a suitable clinical response even before the symptoms arise.

DeepUll (Barcelona, Spain), a biotech company, is creating rapid, affordable and accessible diagnostic solutions with a specific focus on culture-free diagnostics to enable sepsis recognition in pre-symptomatic patients. DeepUll’s technology aims to not only rapidly identify the causative infective agent(s) within a few hours, but will also provide phenotypic antimicrobial susceptibility results, thus reducing the unnecessary use of antimicrobials. The product will also utilize artificial intelligence (AI) to offer seamless medical decision support across all phases of patient management, from early disease recognition, to precise diagnostics, up to therapy guidance.

DeepUll’s first-in-class sepsis recognition platform is designed to detect more than 250 different pathogens and about 15 resistance genes in one hour starting from 10mL of whole blood. The product will generate phenotypic antimicrobial susceptibility results in about eight hours, without requiring a positive blood culture. The product will be a desktop system with end-to-end automation with the aim to be placed in any clinical setting (laboratory, ER, ICU).

“Early identification of sepsis is absolutely crucial to a patient’s prognosis, but the tools caregivers have available today are woefully inadequate,” said Jordi Carrera, Chief Executive Officer and Co-Founder of DeepUll. “Our mission is to change this and this financing will allow us to ramp up our efforts to bring our first-in-class sepsis recognition platform to market.”

Related Links:
DeepUll

Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Dual Chamber Warming Cabinet
D-Series
New
Enteral Feeding Pump
Instilar 1420

Print article

Channels

Critical Care

view channel
Image: A mechanosensing-based approach offers a potential path to the treatment for cardiac fibrosis (Photo courtesy of Adobe Stock)

Mechanosensing-Based Approach Offers Promising Strategy to Treat Cardiovascular Fibrosis

Cardiac fibrosis, which involves the stiffening and scarring of heart tissue, is a fundamental feature of nearly every type of heart disease, from acute ischemic injuries to genetic cardiomyopathies.... Read more

Surgical Techniques

view channel
Image: Bioprinting synthetic vasculature could dramatically change how cardiovascular diseases are treated (Dell, A.C., Maresca, J., Davis, B.A. et al.; doi.org/10.1038/s41598-025-93276-y)

Bioprinted Aortas Offer New Hope for Vascular Repair

Current treatment options for severe cardiovascular diseases include using grafts made from a patient's own tissue (autologous) or synthetic materials. However, autologous grafts require invasive surgery... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more